Izra-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and facilitating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective acid control and promoting mucosal healing in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation of Izra-L Capsule ensures prolonged therapeutic plasma concentrations, optimizing symptom relief and improving patient compliance through once-daily dosing. This combination is particularly beneficial in patients with overlapping motility and acid-related disorders, offering a dual mechanism of action that addresses both delayed gastric emptying and acid hypersecretion. Izra-L Capsule SR should be used under medical supervision, with consideration of contraindications such as hypersensitivity to components, and caution in patients with renal or hepatic impairment. Adverse effects may include headache, dizziness, diarrhea, or abdominal discomfort, and patients should be monitored for any unusual symptoms during therapy.